| Literature DB >> 35092559 |
Behrouz Shademan1, Sepideh Masjedi2, Vahidreza Karamad1, Alireza Isazadeh3, Fatma Sogutlu1, Mohammad Hosein Saeedi Rad4, Alireza Nourazarian5.
Abstract
A novel gene editing tool, the Cas system, associated with the CRISPR system, is emerging as a potential method for genome modification. This simple method, based on the adaptive immune defense system of prokaryotes, has been developed and used in human cancer research. These technologies have tremendous therapeutic potential, especially in gene therapy, where a patient-specific mutation is genetically corrected to cure diseases that cannot be cured with conventional treatments. However, translating CRISPR/Cas9 into the clinic will be challenging, as we still need to improve the efficiency, specificity, and application of the technology. In this review, we will explain how CRISPR-Cas9 technology can treat cancer at the molecular level, focusing on ordination and the epigenome. We will also focus on the promise and shortcomings of this system to ensure its application in the treatment and prevention of cancer.Entities:
Keywords: CRISPR; Cancer treatment; Gene editing; Solid tumors
Mesh:
Year: 2022 PMID: 35092559 DOI: 10.1007/s10528-022-10193-9
Source DB: PubMed Journal: Biochem Genet ISSN: 0006-2928 Impact factor: 2.220